XTL Biopharmaceuticals Announces First Half 2008 Financial Results

VALLEY COTTAGE, N.Y., Aug. 14  /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL), a biopharmaceutical company engaged in the acquisition and development of therapeutics for the treatment of unmet medical needs, particularly diabetic neuropathic pain and hepatitis C, today announced its financial results for the first half ended June 30, 2008.

At June 30, 2008, the Company had cash, cash equivalents and short-term bank deposits of $8.3 million, compared to $13.0 million at December 31, 2007. The decrease of $4.7 million during the six months ended June 30, 2008 was attributable primarily to operating expenditures associated with the Company's ongoing Bicifadine clinical program and to the preclinical hepatitis C program, which was out-licensed to Presidio Pharmaceuticals, Inc., or Presidio, at the end of March 2008, offset by the $4.0 million upfront license payment received from Presidio. The Company's cash, cash equivalents and short-term bank deposits of $8.3 million at June 30, 2008 does not reflect the $2 million due to XTL pursuant to the amendment of the Presidio license that was signed last week.

The loss for the six months ended June 30, 2008 was $7.1 million, or $0.02 per ordinary share, compared to a loss of $14.6 million, or $0.07 per ordinary share, for the comparable period last year, representing a decrease in net loss of $7.5 million. The decreased loss was primarily attributable to a $4.5 million decrease in research and development costs and the recognition in the 2008 period of the $4.0 million upfront license fee received from Presidio. The $4.5 million decrease in research and development costs was primarily due to the absence in the current period of the $7.5 million initial license fee for Bicifadine incurred during the comparable period last year and the absence of $1.3 million in expenses related to the Company's legacy hepatitis C clinical programs, offset by a $5.3 million increase in expenses associated with the ongoing Bicifadine clinical program.  For the six months ended June 30, 2008 and 2007, the Company's losses of $7.1 million and $14.6 million, respectively, included $1.3 million and $1.0 million, respectively, of non- cash stock option compensation expense and also included the recognition of a $0.7 million and $0.6 million charge recorded during the current and comparable period last year relating to the fair-value of stock appreciation rights granted as a transaction advisory fee to certain third party intermediaries in connection with the Bicifadine transaction.

Commenting on the results, Ron Bentsur, Chief Executive Officer of XTL, said, "During the first half of 2008, we consummated the out-licensing of our preclinical hepatitis C program to Presidio Pharmaceuticals, Inc." Mr. Bentsur added, "In June we completed patient randomization into our multi-center, double-blind, placebo-controlled Phase 2b clinical trial with Bicifadine in diabetic neuropathic pain.  We remain focused on completing this study and expect to announce results in the fourth quarter of 2008."

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program.  XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:XTLB) ( TASE: XTL) .

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future financial performance, clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, and for our compounds from our hepatitis C pre-clinical program which was recently out-licensed to Presidio Pharmaceuticals, Inc., growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially is our ability to complete in a timely and cost effective manner clinical trials on Bicifadine, which could directly impact our ability to continue to fund our operations; our ability to meet anticipated development timelines for all of our drug candidates due to recruitment, clinical trial results, manufacturing capabilities or other factors; the success of our drug development and marketing arrangements with third parties; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2008, including Risks Related to Our Financial Condition. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com/. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

                       XTL Biopharmaceuticals Ltd.
                   Selected Consolidated Financial Data
        (Thousands of US Dollars, Except Share and Per Share Data)


  Statements of Operations Information:
                                                   Six months ended June 30,
                                                         (unaudited)
                                                     2008           2007
                                                  ---------      ---------
  License Revenues                                   $3,940           $227
  Cost of license revenues (with respect
   to royalties)                                         --             27
                                                  ---------      ---------
  Gross margin                                        3,940            200
                                                  ---------      ---------
  Research and development costs
   (includes $7,500 initial upfront license
   fee for the six months ended June 30, 2007
   and also includes non-cash stock option
   compensation of $100 and $66, for the six
   months ended June 30, 2008 and 2007,
   respectively)                                      7,564         12,118
  Less - participations                                  --             56
                                                  ---------      ---------
                                                      7,564         12,062
  General and administrative expenses
   (includes non-cash stock option compensation
   of $1,115 and $892, for the six months ended
   June 30, 2008 and 2007, respectively)              2,676          2,523

  Business development costs (includes
   stock appreciation rights compensation of
   $688 and $565, and also includes non-cash
   stock option compensation of $48 and $11,
   for the six months ended June 30, 2008 and
   2007, respectively)                                  960            828
                                                 ----------      ---------
  Operating loss                                      7,260         15,213
  Financial and other income, net                       158            351
                                                 ----------      ---------
  Loss before income taxes                            7,102         14,862
  Income taxes                                           13           (213)
                                                 ----------      ---------
  Loss for the period                                $7,115        $14,649
                                                 ==========      =========
  Basic and diluted loss per ordinary share           $0.02          $0.07
                                                 ==========      =========
  Weighted average number of shares
   used in computing basic and diluted loss
   per ordinary share                           292,732,918    220,145,233
                                               ============   ============



  Balance Sheet Information:
                                                   June 30,    December 31,
                                                     2008         2007
                                                  (unaudited)   (audited)
                                                  ----------    ----------
  Assets
  Current assets:
    Cash and cash equivalents                         $3,088        $2,377
    Short-term bank deposits                           5,200        10,600
    Other receivables and prepaid expenses               857           924
                                                  ----------    ----------
      Total current assets                             9,145        13,901
                                                  ----------    ----------
  Employee severance pay funds                            45            48
  Restricted long-term deposits                           62            61
  Property and equipment - net                            83           106
  Intangible assets - net                                 --            11
  Other Assets                                            50            --
                                                  ----------    ----------
      Total assets                                    $9,385       $14,127
                                                  ==========    ==========
  Liabilities and shareholders' equity
  Current liabilities:
    Accounts payable and accrued expenses             $4,237        $3,809
    Other current liabilities (stock
     appreciation rights)                              2,248         1,560
                                                  ----------    ----------
      Total current liabilities                        6,485         5,369
                                                  ----------    ----------
  Liability in respect of employee severance
   obligations                                           155           194
                                                  ----------    ----------
  Commitments and contingencies
      Total liabilities                                6,640         5,563
                                                  ----------    ----------
  Shareholders' equity:
  Ordinary shares of NIS 0.02 par value
   (500,000,000 authorized, 292,805,326 and
   292,654,785 issued and outstanding, at June
   30, 2008 and December 31, 2007, respectively)       1,445         1,444
  Additional paid in capital                         148,277       146,982
  Deficit accumulated during the development
   stage                                            (146,977)     (139,862)
                                                  ----------    ----------
      Total shareholders' equity                       2,745         8,564
                                                  ----------    ----------
      Total liabilities and shareholders' equity      $9,385       $14,127
                                                  ==========    ==========


DATASOURCE: XTL Biopharmaceuticals Ltd.



CONTACT:  Ron Bentsur, Chief Executive Officer of XTL Biopharmaceuticals

Ltd., [phone] ext. 225



Web site: http://www.xtlbio.com/ 

Copyright